Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Thymogen and Vilon — mechanism, dosing, side effects, legal status, and pricing.
Thymogen (also marketed as Thymagen) is a synthetic dipeptide, L-Glu-L-Trp (Glu-Trp), originally isolated by the Khavinson group from the calf-thymus polypeptide complex Thymalin and then synthesized. It is registered as a pharmaceutical in Russia for immunocorrection (nasal drops / IM injection). Not FDA-approved in the US; research-use only.
Vilon is a synthetic dipeptide (Lys-Glu / KE) from the Khavinson bioregulator series, originally derived from thymus extracts and studied in Russian preclinical models as an immunomodulator and geroprotector. Not FDA-approved; all published evidence originates from a single research group.
Thymogen
Vilon
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
Dosing Notes
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Thymogen
Vilon
COA corpus from Disclosed Labs — independently tested batches only.
Thymogen
11
COAs
99.7%
Avg purity
5
Labs
Vilon
11
COAs
99.7%
Avg purity
6
Labs
Evidence base is single-lab (Khavinson and collaborators). A 12-month rat study (Anisimov, Khavinson, Morozov, Biogerontology 2000) reported extended maximum lifespan and reduced spontaneous tumor incidence. Russian clinical reports claim benefit in acute/chronic respiratory infections and post-surgical immunodeficiency; these have not been independently reproduced in Western RCTs.
Key references
Evidence is limited to Khavinson-group preclinical work. Khavinson & Anisimov (Dokl Biol Sci, 2000; PMID 10944717) reported that Vilon (L-Lys-L-Glu) inhibited spontaneous tumor growth and extended lifespan in CBA mice. A small Russian report on Vilon as an adjuvant in elderly colorectal-cancer patients (Kuznik et al., 2005; PMID 16075684) is non-randomized and unreplicated. No Western-framework clinical trials, pharmacokinetic, or dose-response studies have been published.
Thymogen and Vilon are both in the Immune category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Side Effects
Contraindications
Lab Testing
Disclosed Labs